The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes (CGM PreDM)
Primary Purpose
Pre-diabetes, Impaired Glucose Tolerance
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
RT-CGM
Sponsored by
About this trial
This is an interventional prevention trial for Pre-diabetes
Eligibility Criteria
Inclusion Criteria:
- Age 18 or older
- Newly diagnosed with pre-diabetes (within the previous 6 months) with a FPG of > or = 110-125mg/dl or an A1c > or = 6% - 6.4%
- Able to independently measure and read finger stick blood glucose levels
- Willing to wear the CGM device for up to 12 weeks during the study period
- Willing to test blood sugar by fingerstick twice per day while wearing the CGM
- DEERS eligible
Exclusion Criteria:
- Using medication for pre-diabetes
- Women who are pregnant, lactating, planning to become pregnant, or without a safe contraceptive method; all female subjects will undergo pregnancy testing via a serum HcG with their initial blood testing.
- Subjects who are taking glucocorticoids, amphetamines, anabolic, or weight-reducing agents during the course of the study.
- Active Duty service members likely to be deployed during the 18-month study period.
Sites / Locations
- Walter Reed National Military Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
RT-CGM
Arm Description
Patients using the RT-CGM for the intervention portion of the study.
Outcomes
Primary Outcome Measures
Differences in blood glucose
Changes in A1c and fasting blood glucose over time and between the intervention and control groups.
Secondary Outcome Measures
Impact of lifestyle changes
Evaluating the impact of lifestyle changes on levels of glycemic control in the control and experimental groups.
Changes in Glucose dynamics
Comparison of intervention and control group on standard measures of glucose dynamics.
Differences in blood pressure.
Objective comparison between the control and experimental group in changes in blood pressure.
Differences in lipids.
Objective comparison between the control group and the experimental group on changes in lipids.
Differences in weight
Objective comparison between the control group and the experimental group on changes in weight.
Changes in medication use
An objective comparison between the control and experimental group on changes in medication use.
Full Information
NCT ID
NCT01741467
First Posted
July 19, 2012
Last Updated
October 18, 2016
Sponsor
Walter Reed National Military Medical Center
Collaborators
DexCom, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01741467
Brief Title
The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes
Acronym
CGM PreDM
Official Title
The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
August 2015 (Actual)
Study Completion Date
August 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Walter Reed National Military Medical Center
Collaborators
DexCom, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will investigate whether real-time continuous glucose monitoring can be used as a tool for behavior change in people with pre-diabetes.
Detailed Description
The protocol is a prospective, non-blinded, randomized controlled study in persons with newly diagnosed pre-diabetes comparing the effects of real-time continuous glucose monitoring (RT-CGM) combined with diet and lifestyle education to those who have diet and lifestyle education alone. During a "wash-in" phase both groups will wear a masked CGM for 1 week at baseline and again after 12 weeks. Those randomized to the RT-CGM will wear it for 4 cycles of 2 week on/1 week off over the next 12 weeks. Both groups will follow-up with their primary care providers as clinically indicated over the next year with quarterly measurements of blood pressure, weight, and BMI. At the end of this period, they will wear a masked CGM for 1 week.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pre-diabetes, Impaired Glucose Tolerance
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
110 (Actual)
8. Arms, Groups, and Interventions
Arm Title
RT-CGM
Arm Type
Experimental
Arm Description
Patients using the RT-CGM for the intervention portion of the study.
Intervention Type
Behavioral
Intervention Name(s)
RT-CGM
Intervention Description
Dexcom Seven+
Primary Outcome Measure Information:
Title
Differences in blood glucose
Description
Changes in A1c and fasting blood glucose over time and between the intervention and control groups.
Time Frame
baseline, 18 months
Secondary Outcome Measure Information:
Title
Impact of lifestyle changes
Description
Evaluating the impact of lifestyle changes on levels of glycemic control in the control and experimental groups.
Time Frame
baseline, 18 months
Title
Changes in Glucose dynamics
Description
Comparison of intervention and control group on standard measures of glucose dynamics.
Time Frame
baseline, 18 months
Title
Differences in blood pressure.
Description
Objective comparison between the control and experimental group in changes in blood pressure.
Time Frame
baseline, 18 months
Title
Differences in lipids.
Description
Objective comparison between the control group and the experimental group on changes in lipids.
Time Frame
baseline, 18 months
Title
Differences in weight
Description
Objective comparison between the control group and the experimental group on changes in weight.
Time Frame
baseline, 18 months
Title
Changes in medication use
Description
An objective comparison between the control and experimental group on changes in medication use.
Time Frame
baseline, 18 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 or older
Newly diagnosed with pre-diabetes (within the previous 6 months) with a FPG of > or = 110-125mg/dl or an A1c > or = 6% - 6.4%
Able to independently measure and read finger stick blood glucose levels
Willing to wear the CGM device for up to 12 weeks during the study period
Willing to test blood sugar by fingerstick twice per day while wearing the CGM
DEERS eligible
Exclusion Criteria:
Using medication for pre-diabetes
Women who are pregnant, lactating, planning to become pregnant, or without a safe contraceptive method; all female subjects will undergo pregnancy testing via a serum HcG with their initial blood testing.
Subjects who are taking glucocorticoids, amphetamines, anabolic, or weight-reducing agents during the course of the study.
Active Duty service members likely to be deployed during the 18-month study period.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Vigersky
Organizational Affiliation
Walter Reed National Military Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Walter Reed National Military Medical Center
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20889-5600
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
17257275
Citation
Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007 Feb;24(2):137-44. doi: 10.1111/j.1464-5491.2007.02043.x.
Results Reference
background
PubMed Identifier
11832527
Citation
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512.
Results Reference
background
PubMed Identifier
16249558
Citation
Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2005 Nov;28(11):2780-6. doi: 10.2337/diacare.28.11.2780.
Results Reference
background
PubMed Identifier
18261504
Citation
Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008 Feb;121(2):149-157.e2. doi: 10.1016/j.amjmed.2007.09.016.
Results Reference
background
PubMed Identifier
21428766
Citation
DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011 Mar 24;364(12):1104-15. doi: 10.1056/NEJMoa1010949. Erratum In: N Engl J Med. 2011 Jul 14;365(2):189. N Engl J Med. 2011 Sep 1;365(9):869.
Results Reference
background
PubMed Identifier
16627376
Citation
Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract. 2006 Jan-Feb;12 Suppl 1:25-30. doi: 10.4158/EP.12.S1.25.
Results Reference
background
PubMed Identifier
17054235
Citation
Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005061. doi: 10.1002/14651858.CD005061.pub2.
Results Reference
background
PubMed Identifier
18779236
Citation
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008 Oct 2;359(14):1464-76. doi: 10.1056/NEJMoa0805017. Epub 2008 Sep 8.
Results Reference
background
PubMed Identifier
21335621
Citation
Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011 Apr;34(4):795-800. doi: 10.2337/dc10-1989. Epub 2011 Feb 19.
Results Reference
background
PubMed Identifier
19675193
Citation
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Bode B, Beck RW, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy KJ, Tamborlane WV, Weinzimer S, Wolpert H. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care. 2009 Nov;32(11):2047-9. doi: 10.2337/dc09-0846. Epub 2009 Aug 12.
Results Reference
background
PubMed Identifier
22100963
Citation
Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2012 Jan;35(1):32-8. doi: 10.2337/dc11-1438. Epub 2011 Nov 18.
Results Reference
background
PubMed Identifier
22442395
Citation
Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012 Apr;35(4):723-30. doi: 10.2337/dc11-1468. Erratum In: Diabetes Care. 2013 Dec;36(12):4173-5.
Results Reference
background
PubMed Identifier
21193625
Citation
American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care. 2011 Jan;34 Suppl 1(Suppl 1):S11-61. doi: 10.2337/dc11-S011. No abstract available.
Results Reference
background
Learn more about this trial
The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes
We'll reach out to this number within 24 hrs